MECOM and leukemia: Intriguingly, a recent study demonstrated that the hypomethylating agent 5-aza-2-deoxycytidine can induce widespread apoptosis in MECOM-high leukemia cells, highlighting its potential as a therapeutic agent for leukemia with MECOM overexpression (17).